Page 1
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Natural Hormones ReplacementAn Evidence and Practice Based Approach
Andres Ruiz, PharmD, MSc, FACA
President/Partner
Stonegate Pharmacy
COPYRIGHT© ACA This document is the property of the American College of Apothecaries.
These materials may not be copied, photocopied, reproduced, translated, or distributed in any form or by any means without the prior written consent of the American College of Apothecaries.
PRESENTED BY THE
AMERICAN COLLEGE OF APOTHECARIES
2830 SUMMER OAKS DRIVE
BARTLETT, TN 38134WWW.ACAINFO.ORG
Page 2
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Disclosures
Andres Ruiz“declare(s) no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.”
The American College of Apothecaries is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Page 3
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Learning Objectives
At the conclusion of this program, the participating pharmacist or technician will be able to:
–Evaluate the various routes of female BHRT administration
–Evaluate the various routes of Testosterone administration
–Discuss the appropriate labs to monitor female BHRT and Testosterone replacement outcomes
–Discuss the appropriate symptoms to follow for optimal female BHRT and Testosterone replacement outcomes
Page 4
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
WOMEN
Page 5
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness and Monitoring• Oral
• Topical
• Sublingual
Page 6
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness: Oral• Estrogen Recommended Dose(s):
•E2: 0.5mg, 1mg, and 2mg •E3: 2mg •Biest (70/30): 2mg, 3mg
• Progesterone Recommended Dose(s):
•100mg, 200mg, 300mg, 400mg
Page 7
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Oral BHRT: P4 & E2
Takahashi
• E3 and Natural Menopause: decreased severity (50%, p< 0.01)
• E3 and Surgical Menopause: decreased severity (80%, p< 0.01)
Padwick
• E2+E3: decreased Hot Flashes (41%, p<0.01), night sweats (56%, p<0.05), and anxiety (44%, p< 0.01)
Hargrove
Fitzpatrick
• E2+P4>CEE+MPA: VM sxs (p< 0.01)
• E2+P4: VM sxs & mood (p< 0.01)
• P4>MPA: VM sxs, anxiety, & mood (p< 0.001)
• P4: VM sxs, anxiety, & mood (p< 0.001)
Page 8
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Progesterone
Page 9
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Oral BHRT: E2 & P4 PK
Simon & de Ligniéres
• P4: 10% BA; 2hr tmax; Term t½ ~17hrs; ~7ng/ml Cmax*; Food increases BA ~5 to 10%
• 5α and 5β pregnanolone: 30%; GABAA
Price
• E2: 10% BA, 7hr tmax; Term t½ ~20hrs; ~35pg/ml Cmax; 1:5 = E2:E1 ratio
Page 10
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Monitoring: Oral
• Patient History and Physical• Questionnaire on symptoms: VM, somatic, and
psychological symptoms• Physical symptoms generally vary greatly from individual
to individual
• Serum Labs recommended
Page 11
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Monitoring: Oral
• Serum Labs: Cycling: draw labs on day 20• BMP, CBC with Hct/Hgb, lipid panel• E2, P4, Testosterone (free and total), DHEA-S, fasting am
cortisol, T4, free T3, and TSH• Caution: Labs are a tool not the goal
•Serum levels to Target:• E2 (30-70pg/ml), P4 (10-20ng/ml), Ttotal (30-50 ng/dl),
Tfree (3-5pg/ml), DHEA-S (75-150ug/dl)
Page 12
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
See the Forest
Page 13
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness and Monitoring• Oral
• Topical
• Sublingual
Page 14
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness: Topical
• Estrogen Recommended QD Dose(s):•Biest (80/20): 0.5mg to 3mg•Biest (70/30): 0.5mg to 2mg•Biest (50/50): 0.5mg to 2mg
•Progesterone Recommended QD Dose(s):•20, 40, 60mg
Page 15
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of BHRT: Topical
Ruiz
• All Topical(N=37) and 3 to 6 months follow-up
• 25% decreased emotional lability (p= 0.04); 25% decreased irritability (p= 0.05)
• Non-Sig decrease 12% anxiety (p= 0.27); 14% NS (p= 0.27); 10% HF (p= 1.0)
• No ADE (i.e. BCA or CHD) noted on follow-ups
Ruiz
• No significant reductions at 1 to 3 months follow-up
• 3 to 6 months: decreased 31% emotional lability (p<0.01); 29% irritability (p=0.02); 31% night sweats (p=0.04)
Sood
• P4: 100mg compounded equal to 100mg Prometrium
• 3mg Biest (80:20): Closest to 0.05mg Vivelle-Dot
• 3mg Biest (80:20): avg increased 50 pg/ml; Vivelle-Dot: avg increased 49 pg/ml
Page 16
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of BHRT: Biest vs Vivelle-Dot
Page 17
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Topical BHRT: P4
Leonetti
• 20mg P4: resolution of vasomotor symptoms at 4 months (83% vs 19%; p<0.001)
Wren
• 32mg P4: Non-sig reduction in VS (-1.0 vs. 0; p=0.07) and anxiety (-1.0 vs. 0; p= 0.10) in 12 weeks
Benster
• 5,20,40,60mg P4: Non-sig reduction in VS 5mg (-0.4; p= 0.22), 20mg (-0.4; p= 0.23), 40mg (-0.6 p= 0.06), and 60mg (-0.4; p=0.23)
Page 18
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Compounded BHRT to Alleviate Moderate to Severe Menopausal Symptoms
Page 19
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Topical BHRT to Alleviate Moderate to Severe Menopausal Symptoms
Page 20
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Topical BHRT to Alleviate Moderate to Severe Mood, VM, & QOL Symptoms at 1-3 months
59%$
63%$
30%$
70%$
38%$
30%$
29%$
44%$
33%$
37%$
64%$
63%$
44%$
63%$
41%$
44%$
25%$
59%$
52%$
48%$
0%$ 10%$ 20%$ 30%$ 40%$ 50%$ 60%$ 70%$ 80%$ 90%$ 100%$
Libido$(n=22)$
Fatigue$(n=27)$
Memory$Loss$(n=27)$
Sleep$Disturbances$(n=27)$
Hot$Flashes$(n=29)$
Night$Sweats$(n=27)$
Depression$(n=24)$
Irritability$(n=27)$
Emotional$Lability$(n=27)$
Anxiety$(n=27)$
Proportion(with(Moderate(to(Severe(Symptoms(
Menopausal(Sym
ptom
s(
Baseline$$ 1$to$3$Months$
p=0.45$
p=0.06$
p=0.38$
p=1$
p=0.29$
p=1$
p=0.73$
p=0.29$
p=1$
p=0.1&
Page 21
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Topical BHRT to Alleviate Moderate to Severe Mood, VM, and QOL Symptoms at 3 to 6 months
54%$
46%$
33%$
71%$
38%$
31%$
25%$
33%$
28%$
28%$
66%$
64%$
45%$
68%$
48%$
51%$
33%$
62%$
59%$
46%$
0%$ 10%$ 20%$ 30%$ 40%$ 50%$ 60%$ 70%$ 80%$ 90%$ 100%$
Libido$(n=35)$
Fatigue$(n=39)$
Memory$Loss$(n=40)$
Sleep$Disturbances$(n=41)$
Hot$Flashes$(n=42)$
Night$Sweats$(n=40)$
Depression$(n=36)$
Irritability$(n=39)$
Emotional$Lability$(n=39)$
Anxiety$(n=39)$
Proportion(with(Moderate(to(Severe(Symptoms(
Menopausal(Sym
ptom
s(
Baseline$$ 3$to$6$$Months$
p=0.09$
*p<0.01$
*p=0.02$
p=0.55$
*p=0.04$
p=0.39$
p=1$
p=0.23$
p=0.09$
p=0.34'
Page 22
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Monitoring: Topical• Patient History and Physical
• Questionnaire on symptoms: VM, somatic, and psychological symptoms
• Physical symptoms generally vary greatly from individual to individual
• Salivary Labs recommended for topical
Page 23
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Monitoring: Topical• Serum Labs: Cycling: draw labs on day 20
• BMP, CBC with Hct/Hgb, lipid panel
• E2, P4, Testosterone (free and total), DHEA-S, fasting am cortisol, T4, free T3, and TSH
• Caution: Labs are a tool not the goal
• Serum levels to Target:
• E2 (0.8-12pg/ml), P4 (200-3000pg/ml), T (40-150pg/ml), DHEA-S (75-150ug/dl)
• 12 wks after initial treatment then 6 and 12 months
• Follow directions on kit very carefully
Page 24
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness and Monitoring• Oral
• Topical
• Sublingual
Page 25
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness: Sublingual
• Estrogen Recommended Dose(s)-Divided:• Biest (70/30) or (50/50): 0.25mg to 1mg
• Dose increase by 0.25mg increments
•Progesterone Recommended Dose(s)-Divided:•100mg to 200mg
Page 26
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of BHRT: Sublingual
Gass
• E2 effectively reduces HF (0.05mg, 0.1mg, 0.2mg, and 0.4 mg/day)
• Digital thermography: 56%, 55%, 57% and 80% reduction in HF frequency, compared to baseline (p<0.05)
• Digital thermography: 0.4mg/day vs. placebo (0.17 vs. 0.65; P < 0.01)
Ahokas
• E2: 1mg SL QD achieved serum levels of 108pg/ml
• 2wks: 19 of 23 women recovered from post-partum depression (MADRS)
• 8wks: all recovered via total MADRS
Price
• 0.25mg E2: ~80% BA, 1hr tmax; Term t½ ~8hrs; ~294pg/ml Cmax; 3:1 = E2:E1 ratio
• 1mg E2:~80% BA, 1hr tmax; Term t½ ~18hrs; ~451pg/ml Cmax; 3:1 = E2:E1 ratio
Page 27
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of BHRT: Sublingual
Ruiz
• 1-3m: reduced 42% anxiety, 38% emotional lability, 36% irritability, 38% night sweats, 31% hot flashes, 35% sleep disturbances, 35% memory loss, 33% fatigue, and 26% loss of libido (p<0.05)
Wren
• 100 P4: 80% BA, 1hr tmax; Term t½ ~8-10hrs; ~9ng/ml Cmax
Page 28
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of SL BHRT: Estradiol
Page 29
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of SL BHRT to Alleviate Moderate to Severe Mood, VM, and QOL Symptoms at 1 to 3 months
0%# 10%# 20%# 30%# 40%# 50%# 60%# 70%# 80%# 90%# 100%#
Libido#(n=23)#
Fatigue#(n=23)#
Memory#Loss#(n=23)#
Sleep#Disturbances#(n=23)#
Hot#Flashes#(n=26)#
Night#Sweats#(n=26)#
Depression#(n=25)#
Irritability#(n=25)#
Emotional#Lability#(n=26)#
Anxiety#(n=26)#
Proportion(with(Moderate(to(Severe(Symptoms(
Menopausal(Symptoms(
Baseline## 1#to#3#Months#
*p<0.01#
*p<0.01#
*p=0.01#
p=0.07#
*p<0.01#
*p=0.04#
*p<0.01#
*p<0.04#
*p=0.04#
*p=0.03#
Page 30
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of SL BHRT to Alleviate Moderate to Severe Mood, VM, and QOL Symptoms at 3 to 6 months
23%$
43%$
30%$
58%$
21%$
30%$
21%$
33%$
18%$
18%$
70%$
80%$
63%$
81%$
64%$
67%$
46%$
67%$
61%$
64%$
0%$ 10%$ 20%$ 30%$ 40%$ 50%$ 60%$ 70%$ 80%$ 90%$ 100%$
Libido$(n=23)$
Fatigue$(n=23)$
Memory$Loss$(n=23)$
Sleep$Disturbances$(n=23)$
Hot$Flashes$(n=33)$
Night$Sweats$(n=33)$
Depression$(n=33)$
Irritability$(n=33)$
Emotional$Lability$(n=33)$
Anxiety$(n=33)$
Proportion(with(Moderate(to(Severe(Symptoms(
Menopausal(Symptoms(
Baseline$$ 3$to$6$$Months$
*p<0.01$
*p<0.01$
*p=0.01$
*p=0.02$
*p<0.01$
*p<0.01$
p=0.09$
*p=0.02$
*p=0.01$
*p<0.01'
Page 31
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Monitoring: Sublingual• Patient History and Physical
• Questionnaire on symptoms: VM, somatic, and psychological symptoms
• Physical symptoms generally vary greatly from individual to individual
• Serum Labs recommended
• No salivary testing-saturates salivary glands
Page 32
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Monitoring: Sublingual• Serum Labs: Cycling: draw labs on day 20
• BMP, CBC with Hct/Hgb, lipid panel• E2, P4, Testosterone (free and total), DHEA-S, fasting am cortisol, T4,
free T3, and TSH• Caution: Labs are a tool not the goal
• Serum levels to Target:• E2 (30-70pg/ml), P4 (10-20ng/ml), Ttotal (30-50 ng/dl), Tfree (3-
5pg/ml), DHEA-S (2-23ng/ml) • 6 wks after initial SL treatment then 6 and 12 months• Labs 3 to 5 hours after morning sublingual therapy
Page 33
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Intake/Questionnaire• Greene climacteric scale
• Evaluates VM, somatic and psychological components
• Can also score for clinical depression or anxiety (score >10)
• Test at baseline and follow-up – Likert Scale
• Other Questionnaires
• NAMS menopause health questionnaire
• The Menopause Rating Scale
• Kupperman index
Page 34
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
8/5/2014 WARMI: GUARANTEED RELIEF OR YOUR MONEY BACK | Warmi | Better Menopause Relief
http://www.bettermenopause.com/warmi-guaranteed-relief-or-your-money-back 2/2
Next: The Warmi Story (node/9)
Reference: J. G. Greene: Maturitas 61 (1-2) 2008 78-84. Not all Warmi Clinical Trial Results are Statistically Significant
Page 35
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
MEN
Page 36
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness
• Topical
• Sublingual
• Supplements
Page 37
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness: Topical TRT
• Testosterone Recommended Dose(s):• 50 to 200mg QAM to upper arm and shoulder
Page 38
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Topical TRT
Guay
• T Gel 1% increases TT and free T into the normal range
• Higher levels are achieved with application to arms/shoulder (548 ± 261 ng/dL) vschest/abdomen (440 ± 173 ng/dL) (P = 0.03) and legs/thighs 398 ± 164 ng/dL) (P = 0.004)
Dobs
• 83% of patients of males achieve normal physiological levels by day 14
• T: 10% BA, 13.6 tmax; Term t½ ~32hrs; ~750pg/ml Cmax; 1:5 = DHT:T ratio
• Increase in SHBG; E2 Levels resorted to normal physiology
Page 39
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Page 40
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Page 41
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness
• Topical
• Sublingual
• Supplements
Page 42
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness: SL TRT
• Testosterone Recommended Dose(s):• 10 to 50mg BID
Page 43
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness of Topical TRT
Korbonits
• In the buccal system group, the mean concentrations at all time points were within the physiological range
• Transdermal patch group, mean concentrations at five timepoints were outside of the physiological range.
• Pts with values outside the physiological range was lower in the buccal system group than transdermal group (P < 0.001)
• T buccally is superior to the transdermal patch
Dobs
• Buccal T significantly elevated levels of T in hypogonadal men and improved both objective and subjective measures of sexual function
• T: 80% BA, 30min tmax; Term t½ ~6rs; ~2790pg/ml Cmax; 1:15 = DHT:T ratio
• No Increase in SHBG; E2 Levels resorted to normal physiology
Page 44
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Page 45
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Page 46
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Effectiveness
• Topical
• Sublingual
• Supplements
Page 47
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Saw Palmetto
• Non-competitively inhibits 5-alpha-reductase (prevents conversion of Testosterone to DHT) which may reduce prostate growth
• However 5-AR levels not reduced in vivo
• Shrinks inner prostatic epithelium (not overall prostate size)
• May inhibit lipoxygenase and COX to reduce inflammation (reduces TNF-alpha and IL-1beta)
• Has anti-estrogen, antispasmodic, and alpha-adrenergic inhibitory properties
Page 48
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Saw Palmetto: Efficacy
• Inconsistent and contradictory evidence
• Mild to Mod improvement of urinary symptoms (freq. urination, painful urination, hesitancy, urgency, perinealheaviness), decreased nocturia, improved urinary flow, lower residual volume.
Page 49
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Saw Palmetto: Safety
• Likely safe
• Pregnancy & lactation – Unsafe• Antiestrogenic effects
Page 50
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Saw Palmetto: Adverse Reactions
• Generally mild and comparable to placebo
• Dizziness, HA, GI(N/V/D/C)
• Asthenia, loss of libido, ejaculation disorders, postural hypotension
Page 51
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Saw Palmetto: Drug Interactions
• Anticoagulants/Antiplatelets - increased risk of bleeding (SP may prolong bleeding time)
• Contraceptives (antiestrogenic effects of SP)
• Estrogens (antiestrogenic effects of SP)
• Conflicting evidence of CYP2D6 & 3A4• In vivo - yes; clinically - no
Page 52
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Saw Palmetto
Page 53
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
• Flavonoid
• Found: passionflower, silver linden, some geranium species, and in honey and bee propolis
• Primary activity: Aromatase inhibitor
• Other activity: inhibits UGT1A1, CYP 1A1 and CYP 1A2
Chrysin
Page 54
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
• Only theoretical for cancer prevention and performance enhancement
• Oral and topical chrysin have very poor bioavailability
• Ineffective?
Chrysin: Efficacy
Page 55
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
• Possibly safe since poorly absorbed
• Orally 300mg QD
• Topicall 50mg to 100mg QD
• Unsafe in pregnancy: no studies to date
Chrysin: Safety
Page 56
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
• No reported to date
Chrysin: Adverse Reactions
Page 57
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Chrysin: Drug Interactions
• Moderate: Aromatase inhibitors
• Minor: Glucuronidated drugs and CYP 1A2
Page 58
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Chrysin:Passion Flower
Page 59
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Case• 62y/o male
• History of vasectomy, apathy, ED, mood disturbances, decreased libido, and sleep disturbances
• E2 40pg/ml; T total=107ng/dvl, Tfree 2.7ng/dl, BMP WNL, CBC WNL
• No h/o of HRT
• How should the patient be treated?
Page 60
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Hook'em
Page 61
E N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O NE N T R E P R E N E U R S H I P | M E N T O R I N G | E D U C A T I O N
Need More Information?
Andres Ruiz, PharmD, MSc, FACA
President/Partner
Stonegate Pharmacies
[email protected]
www.stonegaterx.com